FoodNov 5, 2025
Doan's Dessert And Coffee Carrot Bundt Cake - Net Weight 4 lbs Contains: Wheat, Soy recall — FDA H-0137-2026
Undeclared allergen ingredient (Wheat) in Ready-to-eat frozen cakes.
Class IFDA: TerminatedDoan's Dessert And Coffee
Monthly breakdown
2025 recalls by month
Select a month to review the recall records reported during that period.
December 202599 records · 3 categoriesNovember 202596 records · 3 categoriesOctober 2025133 records · 3 categoriesSeptember 2025115 records · 3 categoriesAugust 202581 records · 3 categoriesJuly 202537 records · 2 categoriesJune 202523 records · 2 categoriesMay 202553 records · 2 categoriesApril 202539 records · 2 categoriesMarch 202530 records · 2 categoriesFebruary 202523 records · 2 categoriesJanuary 202525 records · 2 categories
2025 recalls — page 8
Records are ordered by the best available source date.
FoodNov 5, 2025
Doan's Dessert And Coffee White Chocolate Coconut Bundt Cake - Net Weight 3 lbs 12 oz recall — FDA H-0138-2026
Undeclared allergen ingredient (Wheat) in Ready-to-eat frozen cakes.
Class IFDA: TerminatedDoan's Dessert And Coffee
FoodNov 5, 2025
Tai Foong USA Fusia Asian Inspirations brand Veggie Spring Rolls recall — FDA H-0143-2026
Undeclared shrimp
Class IFDA: TerminatedTai Foong USA Inc
DrugNov 5, 2025
Desipramine Hydrochloride Tablets, USP, 75 mg, 100 count bottle (NDC 23155-581-01) recall — FDA D-0110-2026
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Class IIFDA: OngoingHeritage Pharmaceuticals Inc
DrugNov 5, 2025
Lisdexamfetamine Dimesylate Capsules, 30 mg, CII, 100-count bottle recall — FDA D-0146-2026
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine…
Class IIFDA: OngoingSUN PHARMACEUTICAL INDUSTRIES INC
DrugNov 5, 2025
Lisdexamfetamine Dimesylate Capsules, 40 mg, CII, 100-count bottle recall — FDA D-0147-2026
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine…
Class IIFDA: OngoingSUN PHARMACEUTICAL INDUSTRIES INC
DrugNov 5, 2025
Endo USA Everolimus tablets 10 mg, 28 tablets recall — FDA D-0141-2026
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
Class IIIFDA: OngoingEndo USA, Inc.
DrugNov 5, 2025
Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90) recall — FDA D-0100-2026
CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
Class IIFDA: OngoingBreckenridge Pharmaceutical, Inc.
DrugNov 5, 2025
Lisdexamfetamine Dimesylate Capsules, 10 mg, CII, 100-count bottle recall — FDA D-0144-2026
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine…
Class IIFDA: OngoingSUN PHARMACEUTICAL INDUSTRIES INC
DrugNov 5, 2025
Prazosin Hydrochloride, Capsules, USP, 5 mg recall — FDA D-0106-2026
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc
DrugNov 5, 2025
Lisdexamfetamine Dimesylate Capsules, 20 mg, CII, 100-count bottle recall — FDA D-0145-2026
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine…
Class IIFDA: OngoingSUN PHARMACEUTICAL INDUSTRIES INC
DrugNov 5, 2025
QuVa Pharma R.E.C.K recall — FDA D-0113-2026
Presence of Particulate Matter
Class IIFDA: OngoingQuVa Pharma, Inc.
DrugNov 5, 2025
Desipramine Hydrochloride Tablets, USP, 100 mg, 100 count bottle (NDC 23155-582-01) recall — FDA D-0111-2026
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Class IIFDA: OngoingHeritage Pharmaceuticals Inc
DrugNov 5, 2025
Desipramine Hydrochloride Tablets, USP, 50 mg, 100 count bottle (NDC 23155-580-01) recall — FDA D-0109-2026
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Class IIFDA: OngoingHeritage Pharmaceuticals Inc
DrugNov 5, 2025
Prazosin Hydrochloride, Capsules, USP, 1 mg, 100 capsules (10x10) cartons recall — FDA D-0101-2026
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
Class IIFDA: OngoingAmerisource Health Services LLC
DrugNov 5, 2025
Lisdexamfetamine Dimesylate Capsules, 70 mg, CII, 100-count bottle recall — FDA D-0150-2026
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine…
Class IIFDA: OngoingSUN PHARMACEUTICAL INDUSTRIES INC
DrugNov 5, 2025
Desipramine Hydrochloride Tablets, USP, 10 mg, 100 - count bottle (NDC 23155-578-01) recall — FDA D-0107-2026
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Class IIFDA: OngoingHeritage Pharmaceuticals Inc
DrugNov 5, 2025
Prazosin Hydrochloride, Capsules, USP, 2 mg, 100 capsules (10x10) cartons recall — FDA D-0102-2026
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
Class IIFDA: OngoingAmerisource Health Services LLC
DrugNov 5, 2025
Endo USA Everolimus tablets 2.5 mg, 28 tablets recall — FDA D-0142-2026
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
Class IIIFDA: OngoingEndo USA, Inc.
DrugNov 5, 2025
Prazosin Hydrochloride, Capsules, USP, 5 mg, 20 capsules (5x4) cartons recall — FDA D-0103-2026
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
Class IIFDA: OngoingAmerisource Health Services LLC
DrugNov 5, 2025
Lisdexamfetamine Dimesylate Capsules, 50 mg, CII, 100-count bottle recall — FDA D-0148-2026
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine…
Class IIFDA: OngoingSUN PHARMACEUTICAL INDUSTRIES INC
DrugNov 5, 2025
Desipramine Hydrochloride Tablets, USP, 150 mg, 50 count bottle (NDC 23155-583-25) recall — FDA D-0112-2026
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Class IIFDA: OngoingHeritage Pharmaceuticals Inc
DrugNov 5, 2025
Samsung Bioepis Co HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled recall — FDA D-0099-2026
Lack of Assurance of Sterility.
Class IIFDA: OngoingSamsung Bioepis Co., Ltd.
DrugNov 5, 2025
Desipramine Hydrochloride Tablets, USP, 25 mg, 100 count bottle (NDC 23155-579-01) recall — FDA D-0108-2026
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Class IIFDA: OngoingHeritage Pharmaceuticals Inc
About the 2025 recall archive
This archive groups records by their reported or recall date. It does not imply that every recall was initiated, announced and resolved during the same calendar year. Open the individual record for the exact dates and source details supplied by FDA or NHTSA.